Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)18.76
  • Today's Change-0.61 / -3.15%
  • Shares traded604.30k
  • 1 Year change-18.40%
  • Beta0.0774
Data delayed at least 15 minutes, as of Feb 12 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

  • Revenue in USD (TTM)13.44bn
  • Net income in USD1.99bn
  • Incorporated2005
  • Employees19.77k
  • Location
    Daiichi Sankyo Co LtdDaiichi Sankyo Bldg. A/B Kan3-5-1, Nihombashi Hon-choCHUO-KU 103-8426JapanJPN
  • Phone+81 362251111
  • Websitehttps://www.daiichisankyo.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Viatris Inc14.12bn-3.69bn18.19bn32.00k--1.20--1.29-3.10-3.1011.9613.130.34172.094.90441,387.50-8.93-0.1756-10.89-0.209639.3640.66-26.13-0.57680.7932.790.4868---4.465.09-1,259.42---3.10--
Roivant Sciences Ltd13.31m-809.24m19.15bn750.00--4.45--1,438.39-1.17-1.170.01936.020.0024----17,746.67-18.265.89-20.806.9891.2190.39-7,558.42639.97----0.000.00-11.19-15.56-111.69---1.32--
Incyte Corp5.14bn1.29bn20.05bn2.84k15.733.8714.533.906.406.4025.6126.040.82914.335.481,807,750.0020.7511.3427.8314.3893.2693.9225.0316.483.25--0.00670.0021.2214.033,844.96---20.67--
United Therapeutics Corp3.13bn1.27bn20.50bn1.31k18.033.1015.146.5526.4126.4164.94153.610.43232.219.782,397,242.0017.5713.6119.4814.8488.5990.7940.6537.816.07--0.000.0023.6314.7121.35--24.11--
Royalty Pharma plc2.38bn770.95m25.84bn100.0025.173.9928.8910.871.781.784.2111.220.1257--84.5223,781,930.007.006.729.039.10----55.6850.56--7.060.479550.525.062.30-10.259.26-4.9024.01
Biogen Inc9.89bn1.29bn28.69bn7.50k22.201.5713.842.908.818.8167.37124.450.34411.045.301,318,747.004.506.705.327.9375.6978.4913.0717.282.035.740.25620.002.22-5.96-20.79-20.22-19.60--
Daiichi Sankyo Co Ltd - ADR13.44bn1.99bn35.92bn19.77k17.513.1014.492.671.071.077.226.050.56490.81833.11679,809.908.38--10.55--77.5472.1514.8411.031.85--0.1495--17.7713.9544.4717.77----
Alnylam Pharmaceuticals, Inc.3.21bn43.57m40.75bn2.23k1,348.37173.82408.0112.700.22880.228824.381.770.70896.837.081,439,493.000.962-20.071.39-25.5183.9084.181.36-55.192.491.030.9146--22.9759.2136.82---24.55--
Data as of Feb 12 2026. Currency figures normalised to Daiichi Sankyo Co Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.31%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (Global Investors)as of 15 Oct 20255.19m0.27%
Azimuth Capital Investment Management LLCas of 30 Sep 2025198.96k0.01%
Ramirez Asset Management, Inc.as of 30 Sep 2025116.25k0.01%
Madison Asset Management LLCas of 31 Dec 2025105.07k0.01%
Nia Impact Advisors LLCas of 30 Nov 202533.84k0.00%
Causeway Capital Management LLCas of 08 Jan 202630.30k0.00%
RhumbLine Advisers LPas of 30 Sep 202526.70k0.00%
Yousif Capital Management LLCas of 31 Dec 202517.07k0.00%
Arctic Asset Management AS (Sweden)as of 01 Jan 202615.36k0.00%
Intelligent Alpha LLCas of 08 Jan 202612.04k0.00%
More ▼
Data from 30 Sep 2025 - 08 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.